2. Gadgieva Z.K. A functional state of lower urinary tract and drug treatment of urinary disorders in women in climacteric period. Diss. kand. med. nauk. M., 2001. Russian (Гаджиева З.К. Функциональное состояние нижних мочевых путей и медикаментозная коррекция нарушений мочеиспускания у женщин в климактерии. Дисс. канд. мед. наук.М., 2001).

3. Tikhomirova E.V. Specific features of manifestations and treatment of urogenital disorders in perimenopausal period. Diss... kand. med. nauk. M., 2005. Russian (Тихомирова Е.В. Особенности клиники и лечения урогенитальных расстройств в перименопаузе. Дисс. канд. мед. наук. М., 2005).

4. Amirova J.S. Optimization of diagnostics and treatment of overactive bladder in women with urogenital disorders in climacteric period. Diss... kand. med. nauk. M. 152 p. Russian (Амирова Ж.С. Оптимизация диагностики и лечения гиперактивного мочевого пузыря у женщин с урогенитальными расстройствами в климактерии. Дисс. канд. мед. наук. 152 с.).

5. Levine K.B., Williams R.E., Hartmann K.E. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008; 15: 661–666.

6. Sarrel P.M. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J Womens Health Gend Based Med 2000; 9: S25–S32. Review. Erratum in: J Womens Health Gend Based Med. 2001; 10: 91.

7. Dennerstein L., Randolph J., Taffe J., et al. Hormones, mood, sexuality, and the menopausal transition. FertilSteril. 2002; 77: S42–S48.

8. Banks J., Batty G.D., Nazroo J., and Steptoe A. The dynamics of ageing: evidence from the English Longitudinal Study of Ageing. 2002–2015 (Wave 7). ESRC & IFS: London, 2016.

9. Samsioe G., Jansson I., Mellstro€m D., et al. Occurrence, nature and treatment of urinary incontinence in a 70- year-old female population. Maturitas. 1985; 7: 335–342.

10. Van Geelen J.M., van de Weijer P.H., Arnolds H.T. Urogenital symptoms and resulting discomfort in non- institutionalized Dutch women aged 50–75 years. IntUrogynecol J Pelvic Floor Dysfunct. 2000; 11: 9–14.

11. Davila G.W., Singh A., Karapanagiotou I., et al. Are women with urogenital atrophy symptomatic? Am J ObstetGynecol. 2003; 188: 382–388.

12. Notelovitz M., Funk S., Nanavati N., et al. Estradiol absorption from vaginal tablets in postmenopausal women. ObstetGynecol. 2002; 99: 556–562.

13. Sturdee D.W., Panay N. International Menopause Society Writing Group. Recommendations for the management of post-menopausal vaginal atrophy. Climacteric. 2010; 13: 509–522.

14. Portman D.J., Gass M.L..S, Kingsberg S., et al Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American Menopause Society Menopause. J North Am Menopause Soc. 2014; 21: 1063–1068.

15. Blakeman P.J., Hilton P., Bulmer J.N. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int. 2000; 86: 32–38.

16. Smith P. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiolreleasing vaginal ring. Acta Obstet Gynecol Scand Suppl. 1993; 157: 1–26.

17. Zhu L, Lang J.H., Feng R.E., et al. Study one strogen receptor around levatorani muscle for female stress urinary incontinence. Zhonghua Fu Chan KeZaZhi 2004; 39: 655–657.

18. Sarrel P.M. Sexuality and menopause. ObstetGynecol. 1990; 75: 26S–30S.

19. Bachmann G.A., Leiblum S.R. The impact of hor- mones on menopausal sexuality: a literature review. Menopause. 2004; 11: 120–130.

20. Laan E., Everaerd W. and Evers A. Assessment of female sexual arousal: response specificity and construct validity. Psychophysiology. 1995; 32: 476–485.

21. Bygdeman M., Swahn M.L. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996; 23: 259–263.

22. Biglia N., Peano E., Sgandurra P., et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010; 26: 404–412.

23. Edwards D., Panay N. Treating vulvovaginal atrophy/ genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016; 19: 151–161.

24. Rosen A.D, Rosen T. Study of condom integrity after brief exposure to over the counter vaginal preparations. South Med J. 1999; 92: 305–307.

25. NICE Menopause guideline: diagnosis and management

26. Suckling J., Lethaby A., Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; (4): CD001500. Review. Update in: Cochrane Database Syst Rev 2016; 8: CD001500. PubMed PMID: 17054136.

27. Al-Baghdadi O., Ewies A.A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009; 12: 91–105.

28. Ulrich L.S., Naessen T., Elia D., et al. VAG-1748 trial investigators. Endometrial safety of ultra-low- dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric. 2010; 13: 228–237.

29. Haspels A.A., Luisi M., Kicovic P.M. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas. 1981;3:321–327.

30. Constantine G.D., Simon J.A., Pickar J.H., et al. REJOICE Study Group. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017; 24: 409–416.

31. Cardozo L, Bachmann G, McClish D, et al. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998; 92: 722–727.

32. Cardozo L., Lose G., McClish D., et al. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. Int Urogynecol J Pelvic Floor Dysfunct. 2001; 12: 15–20.

33. Cardozo L., Lose G., McClish D., et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004; 83: 892–897.

34. Sant M., Galea P, Brincat M.P. A comparative study between oestrogen replacement therapy, anticho- linergic treatment and a combination of both in the management of detrusor instability in postmenopausal women. In: Book of Abstracts, The 10th World Congress on the menopause, Berlin 2002.

35. NICE Urinary incontinence in women: management clin- ical guideline nice.org.uk/guidance/cg171 (2015).

36. Fantl J.A., Cardozo L., McClish D.K. Estrogen therapy in the management of urinary incontinence in postmen- opausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994; 83(1): 12–18.

37. Henalla SM, Hutchins CJ, Robinson P, et al. Non-opera- tive methods in the treatment of female genuine stress incontinence of urine. J Obstet Gynaecol. 2009; 9: 222–225.

38. Nappi R.E., Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) – results from an inter- national survey. Climacteric. 2012; 15: 36–44.

39. Woyka J., Tanna N., Abernthy K., et al. A menopause service for women with breast cancer or at high risk from breast cancer. EJSO. 2009; 35: 1226–1227.

40. Portman D., Palacios S., Nappi R.E., et al. Ospemifene, a non- oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopaus- al vulvar and vaginal atrophy: a randomised, placebo- controlled, phase III trial. Maturitas. 2014; 78: 91–98.

41. Constantine G., Graham S., Portman D.J., et al. Female sexual function improved with ospemifene in post- menopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015; 18: 226–232.

42. Cui Y., Zong H., Yan H., et al. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014; 11: 487–497.

43. Salvatore S., Pitsouni E., Del Deo, et al. Sexual function in women suffering from genitourinary syndrome of meno- pause treated with fractionated CO(2) laser. Sex Med Rev. 2017; 5: 486–494.

44. Gambacciani M., Levancini M., Russo E., et al. Long-term effects of vaginal erbium laser in the treatment of genito- urinary syndrome of menopause. Climacteric. 2018; 21: 148–152.

45. Mikic A.N., et al. 415 Use of vaginal erbium laser in treat- ment of vaginal relaxation syndrome and pelvic floor dys- function. JISM 2017; 14: S126–S127.

46. Labrie F., Archer D.F., Koltun W., et al. Efficacy of intra- vaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016; 23: 243–256.

47. Labrie F., Archer D.F., Bouchard C., et al. Prasterone has parallel beneficial effects on the main symptoms of vul- vovaginal atrophy: 52-week open-label study. Maturitas. 2015; 81(1): 46–56.

48. Mario Preti; Pedro Vieira-Baptista; Giuseppe Digesu; Carol Bretschneider;MargotDamaser; OktayDemirkesen; Debra Heller; NasideMangir; Claudia Marchitelli The Clinical Role of LASER for Vulvar and Vaginal Treatments in Gynecology and Female Urology: An ICS/ISSVD Best Practice Consensus DocumentJournal of Lower Genital Tract Disease. 23(2):151–160, APRIL 2019.

49. BMS – Consensus statement Joan Pitkin; on behalf of the British Menopause Society medical advisory council Post Reproductive Health. 2018;24(3):133–138.